BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32224016)

  • 1. Antibody-Mediated Rejection Treatment With Bortezomib in Renal Transplant Recipients: A Single-Center 24-Month Follow-up Case Report.
    Bahena Méndez J; López Y López LR; Sebastián Díaz MA; Trejo Curiel I; Galindo-Lopéz R; Baca Córdova A; Wasung de Lay M; Vázquez Dávila RA; Zarate Rodríguez PA; Carmona-Escamilla MA
    Transplant Proc; 2020 May; 52(4):1123-1126. PubMed ID: 32224016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
    Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
    Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
    Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
    Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
    Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
    Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
    Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.
    Nguyen S; Gallay B; Butani L
    Pediatr Transplant; 2014 Aug; 18(5):463-8. PubMed ID: 24814755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection.
    Lichvar AB; Tremblay S; Leino AD; Shields AR; Cardi MA; Abu Jawdeh BG; Govil A; Kremer J; Cuffy M; Paterno F; Diwan T; Brailey P; Girnita A; Alloway RR; Woodle ES
    Transplantation; 2020 Nov; 104(11):2403-2414. PubMed ID: 32000256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Plasma Cell-Rich Acute Rejection in Living-Related Kidney Transplant: Role of Proteasome Inhibitor.
    Abbas K; Mubarak M; Zafar MN; Musharraf W; Imam M; Aziz T; Rizvi AH
    Exp Clin Transplant; 2019 Feb; 17(1):42-46. PubMed ID: 29534661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
    Lee J; Kim BS; Park Y; Lee JG; Lim BJ; Jeong HJ; Kim YS; Huh KH
    Yonsei Med J; 2015 Nov; 56(6):1638-42. PubMed ID: 26446648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Anti-A/B Antibody-Mediated Rejection After ABO-Incompatible Kidney Transplantation Treated With Bortezomib and Plasmapheresis: A Case Report.
    Lee JH; Lee H; Kim K; Lee SW; Song JH; Hwang SD
    Transplant Proc; 2022 Mar; 54(2):540-543. PubMed ID: 35067375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?
    Vacha M; Chery G; Hulbert A; Byrns J; Benedetti C; Finlen Copeland CA; Gray A; Onwuemene O; Palmer SM; Snyder LD
    Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 27988971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study.
    Slatinska J; Slavcev A; Honsova E; Hruba P; Kratochvilova I; Rohal T; Viklicky O
    HLA; 2018 Dec; 92 Suppl 2():47-50. PubMed ID: 30168284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of sensitized pediatric patients prior to renal transplantation.
    Pirojsakul K; Desai D; Lacelle C; Seikaly MG
    Pediatr Nephrol; 2016 Oct; 31(10):1691-8. PubMed ID: 26801944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.